CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

By Castillo Jorge J   Furman Michael   Winer Eric S  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 15-22

Informa Healthcare

Access to resources Recommend Favorite

Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity

By Uckun Fatih M   Qazi Sanjive  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 11, 2010-11 ,pp. : 1457-1470

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

By Robak Tadeusz   Robak Ewa  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 921-947

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

By Prada Patricia O  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 751-763

Informa Healthcare

Access to resources Recommend Favorite

Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer

By  

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 575-576

Bentham Science Publishers

Access to resources Recommend Favorite